RALEIGH, NC (August 9, 2004)/PR Newswire — Erimos Pharmaceuticals announced today that the results of an Open-label, Phase I, Dose Escalation Study of Intralesional Injection of EM-1421 in Head and Neck Cancer was presented by Terry A. Day, M.D at the 6th International Conference on Head and Neck Cancer in Washington, D.C., sponsored by the American Head and Neck Cancer Society. Dr. Day is the Associate Professor, Department of Otolaryngology—Head & Neck Surgery, Medical University of South Carolina and Director of the Division of Head & Neck Oncologic Surgery, Hollings Cancer Center, Medical University of South Carolina. 
 
The study showed that EM-1421-IT administered at 20mg/cm3 up to a maximum total administered dose of 1485mg appears to be tolerable and not associated with systemic side effects. EM-1421-IT produced visible tumor necrosis in 5 of 6 patients with refractory head and neck tumors completing three doses of the drug.

​

About Erimos Pharmaceuticals

Erimos is an emerging, privately-held biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to prevent and treat serious diseases, including cancer. EM-1421 is a small molecule drug which temporarily and reversibly prevents cell division and selectively induces cell death in tumor cells. Erimos has two clinical trial programs. The lead candidate will begin Phase I/II intravenous clinical trials in early 2005 for solid refractory tumors. A second clinical program will begin Phase II clinical trials in 2004 for cervical intraepithelial neoplasia (CIN) and Human Papilloma Virus (HPV). Pre-clinical programs are underway to create groundbreaking treatments for other serious diseases including Alzheimer’s Disease, diabetes, psoriasis, obesity and infectious disease.

​

CONTACT:

​

Cindy Clark
Chief Business Officer
Erimos Pharmaceutical LLC
530 Main Campus Dr., Suite 100
Raleigh, NC 27606
919-821-5204
cclark@erimos.com